| Literature DB >> 16406507 |
R Hoekstra1, F Y F L de Vos, F A L M Eskens, E G E de Vries, D R A Uges, R Knight, R A Carr, R Humerickhouse, J Verweij, J A Gietema.
Abstract
We performed a phase I study with the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 combined with 5-fluorouracil and leucovorin (5-FU/LV) to determine safety profile and assess pharmacokinetic interactions. Patients with advanced solid malignancies received LV 20 mg/m(2) followed by 5-FU 425 mg/m(2) both administered intravenously in 15 min daily for 5 days every 4 weeks. ABT-510 was administered subcutaneously twice daily continuously from day 2 onwards. Blood and urine samples for pharmacokinetic analyses were collected at days 1, 5 and 22. Twelve patients received a total of 45 cycles of 5-FU/LV combined with ABT-510. ABT-510 dose levels studied were 50 and 100 mg. The combination was well tolerated, with a toxicity profile comparable to that of 5-FU/LV alone. At the dose levels studied no significant pharmacokinetic interactions were observed. These data indicate that ABT-510 administered twice daily subcutaneously can be safely combined with 5-FU/LV administered daily for 5 days, every 4 weeks.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16406507 DOI： 10.1016/j.ejca.2005.08.040
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162